NUSNu Skin Enterprises, Inc.
The Read
Nu Skin Enterprises (NUS) has historically reacted to regulatory and generic catalysts with a median absolute move of about 17%.
The schedule
- Thu15Oct
Launch of refreshed beauty and wellness products and an enhanced digital/social commerce strategy off a base price of $7.0, with a successful rollout lifting the stock to $8.0 and a muted reception leaving it at $6.0.
- Tue15Dec
Policy review under President Trump on cross‑border e‑commerce and tariffs, with Nu Skin trading at $6.5, a benign or supportive outcome taking the stock to $7.3 and a more restrictive stance driving it to $5.3.
- Fri12Feb
- Tue4May
Q3 2026 earnings and management’s initial 2027 outlook guidance with the stock at $8.0, offering a favorable scenario to $9.0 and a downside scenario back to $6.5.
Past
- Wed30Sep
Potential disclosure of strategic alternatives or renewed activist pressure around a base price of $5.4, with a constructive outcome driving the stock to $7.0 and a failed or delayed process leaving it at $4.6.
- Fri7Aug
Q2 2026 earnings at a depressed base price of $4.5, with a favorable stabilization case taking the stock to $5.4 and a renewed disappointment scenario pushing it to $3.9.
- Wed1Jul
Potential tightening of direct selling and MLM rules in China around a base price of $5.3, with a relief scenario lifting the stock to $6.0 and an adverse enforcement outcome driving it to $4.5.
- Mon1Jun
Actual outcome: Bear · $5.47 at outcome
Despite being highlighted in value and low price-to-sales screens, NUS shares drifted lower and eventually breached the $5.30 bear floor by late June. In the absence of positive updates to dispel concerns over a potential distributor and sales leader exodus, ongoing fundamental uncertainty continued to weigh heavily on the stock.
Ongoing risk that key sales leaders or distributors exit the network following Q1 changes, with the stock anchored at $6.3, a favorable containment scenario at $7.0, and a downside scenario at $5.3 if attrition accelerates.
- Fri8May
Actual outcome: Bear · $6.12 at outcome
Nu Skin reported Q1 2026 adjusted earnings of $0.14 per share, missing consensus estimates of $0.15, alongside a 12% year-over-year decline in revenue to $320.6 million. The top- and bottom-line misses, coupled with management's commentary on ongoing macroeconomic pressures on consumers and supply chains, drove the stock well below the bear floor.
Q1 2026 results and updated commentary on the 2026 recovery plan at a base price of $7.29, with a favorable outcome scenario at $8.1 and a bearish scenario at $6.3.
- Wed1Apr
Actual outcome: Mixed · $7.30 at outcome
Nu Skin announced the general consumer availability of its AI-powered Prysm iO nutritional wellness platform in the U.S. However, the update lacked specific sales momentum or adoption rate metrics to drive a strong directional move, leaving the stock flat and trading between the bull and bear targets.
Management update on the adoption rates of the latest connected beauty devices.
- Fri13Feb
Actual outcome: Bear · $8.66 at outcome
While Q4 EPS met expectations at $0.30, Nu Skin failed to deliver the anticipated floor for revenue declines or a tight 2026 guidance range. The lack of clear management visibility and ongoing top-line struggles confirmed the bear case, driving the stock well below the $9.00 bear floor as investors priced in continued fundamental weakness.
